(AOF) – Beyfortus reduced the risk of hospitalization due to respiratory syncytial virus (RSV) by 82% in infants under six months of age compared with infants who were not immunized against RSV, according to interim results from an ongoing study. published in The Lancet. These results are part of a three-year Nirse-Gal study conducted in Galicia (Spain) in collaboration with the General Directorate of Public Health of the Regional Administration of the Autonomous Community of Galicia (Xunta de Galicia) and Sanofi. .
AOF – LEARN MORE
Find out more about the pharmaceutical sector
Oncology is a priority for pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underscores the group’s new direction, which has now made oncology its number one priority. Efforts in this segment, where treatments are developing fastest, are primarily due to investments in research and development, which are putting pressure on it. profitability. Sanofi therefore announced it would cut its earnings per share in 2024 and abandon its goal of delivering an operating margin of 32% in 2025. Merck just announced a new alliance. It will pay up to $22 billion to Japanese group Daiichi Sankyo as part of a partnership to develop experimental cancer treatments. While some experts estimate that the United States accounts for nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, China’s spending in this area has more than doubled in five years, rising from 5 to 11. 8 billion dollars.
Related Posts
Here’s the best day to peak, according to science
“I’m an exterminator, and here’s the best advice on how to get rid of moths and bedbugs.”
